The Telangana Drugs Control Administration (DCA) today alerted the public that the Government of India had prohibited the manufacture, sale and distribution of oral Nimesulide formulations above 100 mg in immediate-release form for human use.
The ban, circulated through a Gazette notification dated December 29, 2025, has come into immediate effect, citing potential risks to human health and the availability of safer alternatives.
The DCA advised the public to stop using such medicines immediately and consult a registered medical practitioner for alternative treatment. Citizens have also been cautioned against purchasing, storing or consuming the banned formulations. The public has been urged to report any violations to the nearest Drugs Inspector or DCA office.
Authorities are taking steps to withdraw the prohibited drug from the market and supply chain across Telangana. The move aims to safeguard public health and ensure responsible drug use across the State.
Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) used for short-term treatment of acute pain, osteoarthritis and dysmenorrhoea, but carries significant risks, especially liver toxicity (hepatotoxicity) and bleeding, leading to bans or restrictions in many countries.